Compare RCAT & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCAT | VIR |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2017 | 2019 |
| Metric | RCAT | VIR |
|---|---|---|
| Price | $8.26 | $11.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $20.00 | $19.43 |
| AVG Volume (30 Days) | ★ 8.7M | 1.7M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | N/A | ★ N/A |
| Revenue | $17,836,382.00 | ★ $68,556,000.00 |
| Revenue This Year | $271.60 | $270.22 |
| Revenue Next Year | $41.21 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 79.95 | N/A |
| 52 Week Low | $5.77 | $4.75 |
| 52 Week High | $18.78 | $11.66 |
| Indicator | RCAT | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 40.90 | 72.23 |
| Support Level | $7.16 | $8.43 |
| Resistance Level | $8.85 | N/A |
| Average True Range (ATR) | 0.63 | 0.61 |
| MACD | -0.17 | 0.23 |
| Stochastic Oscillator | 1.69 | 100.00 |
Red Cat Holdings Inc is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Its suite of solutions includes the Arachnid family of ISR and precision strike drones, which includes the Black Widow, a small unmanned ISR system; and WEB (Warfighter Electronic Bridge) GCS, designed to command and control an entire drone family of systems for military operations. Its other offerings include Edge 130 Blue drone systems, Trichon, a fixed-wing VTOL for extended endurance and range, and FANG FPV drones optimized for military operations with precision strike capabilities. The firm's Division includes Teal, FlightWave, and Blue Ops.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.